RGEN Stock - Repligen Corp.

RGEN Stock Chart

RGEN Profile

Repligen Corporation specializes in the development and global commercialization of bioprocessing technologies and systems essential for biological drug manufacturing across North America, Europe, the Asia Pacific, and other international markets. The company's portfolio includes Protein A ligands, critical components of Protein A affinity chromatography resins used in biologics purification, alongside cell culture growth factors crucial for optimizing cell growth and productivity.

Central to Repligen's offerings are its chromatography products, featuring OPUS pre-packed chromatography columns for biologics purification and smaller-scale columns utilized in high throughput screening and process development. The company also provides ELISA test kits, chromatography resins branded as CaptivA, and a variety of filtration products such as XCell Alternating Tangential Flow systems and TangenX flat sheet cassettes, vital for biologic drug concentration and formulation processes.

In addition to its bioprocessing solutions, Repligen offers a range of process analytics products, including slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. These advanced analytics tools support precise monitoring and optimization of bioprocessing operations, ensuring quality and efficiency in drug manufacturing.

Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen Corporation serves a diverse customer base including life sciences, biopharmaceutical, and diagnostic companies, as well as contract manufacturing organizations. The company actively pursues collaboration agreements, exemplified by its partnership with Navigo Proteins GmbH, aimed at advancing the development of multiple affinity ligands to further enhance bioprocessing capabilities worldwide.

RGEN Revenue Chart

RGEN Earnings

Analyst Ratings